NPCENeuroPace Inc

Nasdaq www.neuropace.com


$ 8.14 $ -0.39 (-4.56 %)    

Friday, 17-May-2024 15:59:13 EDT
QQQ $ 451.63 $ -1.09 (-0.24 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.31 (0.06 %)
TLT $ 91.40 $ -0.22 (-0.24 %)
GLD $ 223.63 $ 1.39 (0.63 %)
$ 8.17
$ 8.50
$ 0.00 x 0
$ 0.00 x 0
$ 8.07 - $ 8.52
$ 3.80 - $ 18.15
52,034
na
231.09M
$ 1.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 06-03-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-neuropace-maintains-18-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates NeuroPace (NASDAQ:NPCE) with a Overweight and maintains $18 price target.

 neuropace-maintains-fy24-revenue-guidance-of-73m-77m-est-75205m

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

 neuropace-q1-2024-gaap-eps-032-beats-033-estimate-sales-18124m-beat-17302m-estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by ...

 wells-fargo-upgrades-neuropace-to-overweight-raises-price-target-to-20

Wells Fargo analyst Lawrence Biegelsen upgrades NeuroPace (NASDAQ:NPCE) from Equal-Weight to Overweight and raises the price...

 jp-morgan-maintains-overweight-on-neuropace-raises-price-target-to-17

JP Morgan analyst Robbie Marcus maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $9 to $17.

 cantor-fitzgerald-maintains-overweight-on-neuropace-raises-price-target-to-18

Cantor Fitzgerald analyst Ross Osborn maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $...

 morgan-stanley-maintains-equal-weight-on-neuropace-raises-price-target-to-13

Morgan Stanley analyst Drew Ranieri maintains NeuroPace (NASDAQ:NPCE) with a Equal-Weight and raises the price target from $...

 neuropace-provides-full-year-2024-revenue-guidance-of-73m-77m-est-74598m

Gross margin to range between 72% and 74%, Total operating expenses to range between $80 million and $84 million, including app...

 recap-neuropace-q4-earnings
Recap: NeuroPace Q4 Earnings
03/05/2024 21:35:06

 neuropace-q4-2023-gaap-eps-023-beats-032-estimate-sales-1801m-beat-1746m-estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.32) by ...

 earnings-scheduled-for-march-5-2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

 earnings-preview-neuropace
Earnings Preview: NeuroPace
03/04/2024 17:01:14

 leerink-partners-initiates-coverage-on-neuropace-with-outperform-rating-announces-price-target-of-22

Leerink Partners analyst Mike Kratky initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Pr...

 lake-street-reiterates-buy-on-neuropace-maintains-12-price-target

Lake Street analyst Frank Takkinen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $12 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION